Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.08B 9.55B 8.79B 8.25B 15.49B 1,048B 15.65B 104B 40.6B 513B 41.6B 40.72B 1,775B P/E Ratio 2026 *
-70x
P/E Ratio 2027 * 48.2x
Enterprise Value 10.56B 9.1B 8.37B 7.85B 14.75B 998B 14.9B 98.98B 38.66B 489B 39.61B 38.77B 1,690B EV / Sales 2026 *
7.06x
EV / Sales 2027 * 4.53x
Free-Float
94.33%
Yield 2026 *
-
Yield 2027 * -
1 day+2.37%
1 week+5.69%
Current month-0.68%
1 month-5.69%
3 months+12.04%
6 months-11.89%
Current year-15.19%
1 week 460.89
Extreme 460.89
500.71
1 month 445.2
Extreme 445.2
535.76
Current year 416.21
Extreme 416.21
598.79
1 year 275
Extreme 275
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Chairman 83 2016-07-21
Director/Board Member 73 2016-06-30
Director/Board Member 68 2016-08-10
Date Insider Type Main position Quantity % Market Cap.
05-31Sell

Chief Technology Officer

-1,042 0.0045%
05-21Sell

Director

-5,682 0.0248%
05-17Sell

Chief Technology Officer

-844 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+2.27%+5.69%+73.26%+93.28% 11.08B
-2.86%-0.26%+57.57%+110.98% 56.42B
-0.34%+2.91%+45.55%+46.87% 44.54B
+0.72%+6.55%-14.32%-19.38% 22.9B
+0.20%+4.24%-3.37%+390.58% 21.21B
-0.51%-5.56%+10.43%-29.97% 16.4B
-1.54%-1.06%+8.10%-39.28% 15.4B
-1.04%+1.96%+26.36%+176.20% 13.35B
+0.96%+6.56%+20.81% - 12.36B
+0.32%+1.60%+96.37%+207.56% 11.15B
Average -0.18%+1.36%+32.08%+104.09% 22.48B
Weighted average by Cap. -0.72%+2.36%+34.11%+97.88%

Financials

2026 *2027 *
Net sales 1.5B 1.29B 1.19B 1.11B 2.09B 141B 2.11B 14.02B 5.48B 69.21B 5.61B 5.49B 239B 2.21B 1.9B 1.75B 1.64B 3.08B 208B 3.11B 20.69B 8.08B 102B 8.28B 8.1B 353B
Net income -199M -171M -157M -148M -278M -18.76B -280M -1.86B -727M -9.19B -745M -729M -31.8B 310M 268M 246M 231M 434M 29.33B 438M 2.91B 1.14B 14.36B 1.16B 1.14B 49.71B
Net Debt -529M -456M -420M -394M -740M -50.01B -747M -4.96B -1.94B -24.49B -1.99B -1.94B -84.75B -1.09B -944M -868M -815M -1.53B -103B -1.55B -10.27B -4.01B -50.66B -4.11B -4.02B -175B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-06-15 492.74 $ +2.49% 132,639
26-06-12 480.77 $ +1.37% 207,461
26-06-11 474.28 $ +0.63% 278,769
26-06-10 471.32 $ -1.17% 287,530
26-06-09 476.89 $ +2.06% 285,812
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
480.77USD
Average target price
678.71USD
Spread / Average Target
+41.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!